Health Check: Bug buster Genetic Signatures' US expansion is a jumbo-sized task
BTC Health makes a (literally) lifesaving sale
The lessons from Sarepta's billion-dollar FDA woes
Gut disease diagnostics provider Genetic Signatures (ASX:GSS) is finding its US market entry more elephantine than first envisaged and has made some changes 'to better align with current strategy and needs'.
On June 4 last year the US Food and Drug Administration (FDA) approved Genetic's Easyscreen, which can detect eight gastrointestinal (GI) parasites accounting for 90% of all tummy bugs.
On the same day the company launched a $30 million capital raise to support the US push and announced a new CEO (former Roche Diagnostics exec Allison Rossiter).
Genetic expected to be selling in the US within 60 to 90 days.
Today, Genetic says the US sales ramp-up has been 'impacted by prospective customers' internal processes, competing priorities, preference for enhanced workflow and uncertainty in the US healthcare environment.'
In part, the company discovered that clients craved more automated sample processing.
In response, Genetic has entered a three-way 'strategic partnership' with a mob called Tecan (lab automation) and Repado (compliant in vitro diagnostics).
This threesome will result in a 'scalable suite of fully automated diagnostic platforms for syndromic testing labs'.
Genetic doesn't mention any dollars, so we presume the financial impact is immaterial.
Speaking of finances, Genetic today reported June quarter sales of $4.4 million.
This was 52% higher than the March stanza, reflecting higher seasonal testing during the Australian flu season.
But turnover was flat on a year-on-year comp.
Having expended a net $5.95 million, Genetic ended the quarter with still-healthy cash of $30.9 million.
Microba GI testing sales are on tract
Still on tummy bugs, microbiome testing outfit Microba Life Sciences (ASX:MAP) has met its guidance with full-year revenue of $15.67 million, 30% higher year on year.
June (fourth) quarter revenue fell 13.5% to $4.2 million, the result of the company shedding a non-core research services business.
Microba has commercialised two clinical tests, to assess and manage GI patients.
The flagship Metaxplore tests assess a range of markers to appraise the GI tract and presents the results in a clear report.
Metapanel is the 'first line' test to determine whether the patient has a pathogen that can be treated simply with antibiotics.
Currently Metaxplore is sold in Australia and the UK, while Metapanel is available locally via the company's partner and biggest shareholder, Sonic Healthcare (ASX:SHL).
Microba chief Dr Luke Reid says Microba has a 'well considered plan' for US rollout, based on creating a beachhead in one city.
Mayne they could swap notes with Genetic's management.
Locally Microba sold 3451 Metaexplore tests during the quarter, up 88%. Microba also sold 266 Metapanel tests here (up 85%) and 429 in the UK (the test was only launched there in May).
Microba recorded net cash outflows of $5.56 million for the quarter, but management affirms the Australian and UK ops should be break-even this year.
BTC Health's PDF format suits investors
One of the more unusual life science plays on the bourse, medical product distributor BTC Health (ASX:BTC) has secured a $500,000 equipment order with Adelaide's Women's and Children's Hospital.
The order is for extracorporeal membrane oxygenation (ECMO) and follows a similar deal with Melbourne's Royal Children's Hospital.
ECMOs take over the work of the heart and lungs when these organs cannot perform their duties.
BTC Health is building a portfolio of diverse yet specialist medical devices, such as heart valves and infusion pumps.
BTC is a valuable pooled development fund (PDF), a remnant of a Keating-era initiative to bolster investment in small business.
PDFs pay only 15% tax on income and capital gains, but any returns to shareholders are tax free.
Only 17 PFDs remain and – like coastal property – God is not creating any more of them.
BTC chief Dr Richard Treagus previously headed generic drug play Acrux, the sector's only other PDF.
BTC posted December half revenue of $5.3 million, with underlying earnings of $200,000.
The company expects to have remained in the black for the full year to June 30 with a 'pathway to sustainable growth'.
Sarepta 'is worth nothing'
Could a $US1.31 billion company really be worth nothing?
US investment bank H.C. Wainwright thinks so, having ascribed a 'price target' of yada and zip to the Sarepta Therapeutics on the back of the Nasdaq-listed entity's drug strife.
Last week the FDA asked Sarepta to voluntarily halt shipments of its Elevidys gene therapy, for muscular dystrophy.
This follows the death of two patients from liver toxicity issues and the third from a separate experimental gene therapy treatment.
Defying the agency, Sarepta said it would continue to ship the therapy to ambulatory patients, but maintain a halt for wheelchair-bound ones.
The deaths pertained to the latter.
The FDA approved Elevidys two years ago for walking patients aged four or older, with the Duchenne muscular dystrophy (DMD) gene mutation.
A year later the agency expanded the assent to non-ambulatory patients.
Sarepta shares shed up to 40% on Friday and a further 5% overnight.
Don't fight City Hall
H.C. Wainwright previously had a US$10 valuation on Sarepta, compared with the stock's overnight close of US$13.32.
The firm describes Sarepta's fight with the FDA as 'unwinnable' and – indeed – you can't beat City Hall.
Elevidys generated US$384 million of net revenue in the December quarter, more than half of Sarepta's total revenue of US$638 million.
The lesson for everyone is that even when drug makers have done the hard yards of developing and commercialising a therapy, success is still not guaranteed.
In one of the best-known cases, in 1999 the FDA approved Merck's Vioxx, for osteoarthritis pain. After racking up billions in sales Merck withdrew the drug from sale in 2004, amid concerns it could cause heart attacks and strokes.
Locally, Percheron Therapeutics (ASX:PER) is reinventing itself after its DMD therapy failed in phase IIb stage last December.
Perhaps the company dodged a bullet by discovering the problems early in the piece, but wounded investors might disagree.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
West Australian
an hour ago
- West Australian
EU may get 15 per cent tariff deal with US: reports
The European Union is heading towards a trade deal with the United States that will result in a broad 15 per cent tariff on EU goods imported into the US, avoiding a harsher 30 per cent levy slated to be implemented from August 1, two EU diplomats say. The rate, which could also extend to cars, would mirror the framework agreement the United States struck with Japan. Officials from the European Commission, which negotiates trade deals on behalf of the 27-member bloc, briefed EU envoys on the state of talks with their US counterparts. US President Donald Trump would ultimately make any final decision on a deal, however. Under the outlines of the potential deal, the 15 per cent rate could apply to sectors including cars and pharmaceuticals and would not be added to long-standing US duties, which average just under five per cent. There could also be concessions for sectors like aircraft, lumber as well as some medicines and agricultural products, which would not face tariffs, the diplomats said. The US administration does not, however, appear willing to lower its current 50 per cent tariff on steel, they said. The Commission said earlier on Wednesday that its primary focus was to achieve a negotiated outcome to avert the threatened 30 per cent tariffs. At the same time it planned to submit counter-tariffs on 93 billion euros ($A166 billion) worth of US goods to EU members for approval. A vote is expected on Thursday although no measures would be imposed until August 7. Germany supported the EU readying countermeasures, a government representative said. If Trump's 30 per cent tariffs are implemented, EU diplomats also said there was broad support among European governments to activate wide-ranging so-called "anti-coercion" measures, which would allow the bloc to target US services and other sectors. The EU appears to be following in the footsteps of Japan, whose agreement with the United States is the most significant Trump has struck since launching his tariff offensive in April. European shares climbed about one per cent, led by car stocks, following the US-Japan announcement. One stand-out feature of that deal was that the same 15 per cent rate applies to cars, compared to the current US tariff of 27.5 per cent, something the EU may want for its own car exports. The US imported vehicles and automotive parts valued at more than $US55 billion ($A84 billion) from Japan last year. EU exports were 47.3 billion euros. Far fewer US cars were sold into the EU or Japanese markets. EU officials say the US has shown little sign of budging on car tariffs but the Japan deal could hint at flexibility. "Whatever the Japanese got will become the minimum for the EU negotiating objectives," said Simon Evenett, professor of geopolitics and strategy at IMD Business School.
Perth Now
an hour ago
- Perth Now
EU may get 15 per cent tariff deal with US: reports
The European Union is heading towards a trade deal with the United States that will result in a broad 15 per cent tariff on EU goods imported into the US, avoiding a harsher 30 per cent levy slated to be implemented from August 1, two EU diplomats say. The rate, which could also extend to cars, would mirror the framework agreement the United States struck with Japan. Officials from the European Commission, which negotiates trade deals on behalf of the 27-member bloc, briefed EU envoys on the state of talks with their US counterparts. US President Donald Trump would ultimately make any final decision on a deal, however. Under the outlines of the potential deal, the 15 per cent rate could apply to sectors including cars and pharmaceuticals and would not be added to long-standing US duties, which average just under five per cent. There could also be concessions for sectors like aircraft, lumber as well as some medicines and agricultural products, which would not face tariffs, the diplomats said. The US administration does not, however, appear willing to lower its current 50 per cent tariff on steel, they said. The Commission said earlier on Wednesday that its primary focus was to achieve a negotiated outcome to avert the threatened 30 per cent tariffs. At the same time it planned to submit counter-tariffs on 93 billion euros ($A166 billion) worth of US goods to EU members for approval. A vote is expected on Thursday although no measures would be imposed until August 7. Germany supported the EU readying countermeasures, a government representative said. If Trump's 30 per cent tariffs are implemented, EU diplomats also said there was broad support among European governments to activate wide-ranging so-called "anti-coercion" measures, which would allow the bloc to target US services and other sectors. The EU appears to be following in the footsteps of Japan, whose agreement with the United States is the most significant Trump has struck since launching his tariff offensive in April. European shares climbed about one per cent, led by car stocks, following the US-Japan announcement. One stand-out feature of that deal was that the same 15 per cent rate applies to cars, compared to the current US tariff of 27.5 per cent, something the EU may want for its own car exports. The US imported vehicles and automotive parts valued at more than $US55 billion ($A84 billion) from Japan last year. EU exports were 47.3 billion euros. Far fewer US cars were sold into the EU or Japanese markets. EU officials say the US has shown little sign of budging on car tariffs but the Japan deal could hint at flexibility. "Whatever the Japanese got will become the minimum for the EU negotiating objectives," said Simon Evenett, professor of geopolitics and strategy at IMD Business School.
Sky News AU
7 hours ago
- Sky News AU
High-level Chinese diplomat probes Newcastle City Lord Mayor for AUKUS submarine location in private meeting
A high-level Chinese diplomat based in Australia has pressed Newcastle City Mayor Ross Kerridge for information on AUKUS nuclear submarines during a private meeting between the pair. Australia's ability to secure nuclear submarines is a main pillar of the trilateral AUKUS security agreement and the country has already committed $3 billion to assist United States defence manufacturing in exchange for being able to purchase Virginia class vessels. However, questions have been raised over the availability of US-built of submarines following the Trump administration's announcement it was reviewing the deal, which Australia sees as a critical defence investment of deterrence in the region. The Daily Telegraph has now revealed an encounter on July 17 where the future docking location of AUKUS submarines was discussed, prompted by the Consul General of China in Syndey, Wang Yu. According to minutes of the meeting obtained by masthead, notes taken show that the diplomat asked if submarines secured under AUKUS would be based at Newcastle. '(Consul General) explained that China is concerned that Chinese interests in Australia will be affected by strategic defence decisions,' the meeting document read, according to the masthead. 'For example, is Newcastle Port a potential base for AUKUS submarines? '(The Lord Mayor) explained that we are a nuclear free city, but we will not have the means to stop a decision of this nature taken by the state and/or federal governments. 'China expects that Australia and Newcastle will have good relations with other countries and is also looking to build good relations, but would not like us… to use our good relations with other countries to adversely affect China.' The Daily Telegraph also reported the New South Wales city's Taiwanese and Tibetan communities were talked about during the meeting. It comes just days after The Australian revealed Shanghai Xinyang Chamber of Commerce president Wang Yongxin's family ties to the purchase of commercial port properties at Newcastle and Kembla. Wang family members have reportedly denied they have links to the Chinese Communist Party's United Front. Meanwhile, there have been suggestions Australia may need to increase its financial commitments to ensure Virginia class submarines are provided in line with the terms of the original AUKUS agreement. Last month, Defence Minister Richard Marles said he was not prepared to "speculate" on the Trump administration's review of the pact and insisted the government's focus was directed at "pursuing the optimal pathway" that would see Virginia class submarines being available to Australia from 2032.
